Biotech

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Biotech Recent News

Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores.
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?
Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement.
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia.
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto stock jumps after acquiring Damora Therapeutics and raising $285 million to advance blood cancer programs through 2029.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved